India’s pharmaceutical sector is under renewed focus after Lilly supported Haryana’s crackdown on fake Mounjaro drug networks, following the seizure of counterfeit products in Gurugram.
The action by the Haryana State Food and Drug Administration highlights growing concerns over fake medicines entering legitimate pharmaceutical supply chains and putting patient safety at risk. Eli Lilly and Company confirmed that the seized products were not manufactured by the company and did not come through its authorised distribution channels.
The investigation was launched after authorities identified suspicious products being sold under the Mounjaro brand name. Drug control officials moved quickly to trace the supply chain and remove fake stock from circulation. The company stated that genuine medicines remain available through licensed distributors and approved pharmacies, ensuring no interruption in access for patients.
Lilly praised the efforts of Haryana regulators for taking timely action against counterfeit medicine networks. Company representatives said fake medicines can create serious health risks because they are not produced under approved manufacturing standards. Such products may contain incorrect ingredients, poor-quality substances, or unsafe formulations that can harm patients.
Also Read: AI Coronary Imaging Breakthrough Elevates PCI Precision
The company also stressed the need for stronger cooperation between pharmaceutical firms, law enforcement agencies, and state regulators to stop the spread of counterfeit drugs. Officials noted that illegal distribution channels often target high-demand medicines, making stricter monitoring essential across the healthcare system.
Patients and healthcare professionals have been advised to remain alert when purchasing medicines. Lilly recommended buying only from licensed pharmacies and ensuring prescriptions are obtained from qualified healthcare providers. Consumers should also inspect packaging details carefully, including batch numbers, expiry dates, and branding consistency, to avoid suspicious products.
Lilly clarified that tirzepatide is marketed in India under the brand names Mounjaro and Yurpeak. The company believes maintaining trust in medicines depends on strong regulation, transparent distribution systems, and increased awareness among consumers. The Haryana case serves as a reminder of the growing challenge posed by counterfeit pharmaceuticals in India’s healthcare industry.
.jpg)
.jpg)
